Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sanofi is fronting $135 million, according to a Tuesday securities filing to the Hong Kong stock exchange. In return, the pharma will have the exclusive right…
Sanofi is deepening its cGVHD franchise, already anchored by the $425-million-a-year Rezurock (belumosudil), with an ex-China license for Chia Tai Tianqing's…
The Sanofi-Chia Tai Tianqing licensing deal marks another ex-China outbound from a Chinese biopharma following the trend set by Summit Therapeutics'…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Sanofi obtained worldwide (global) exclusive rights to develop, manufacture and commercialize Chia Tai Tianqing Pharmaceutical Group's (CTTQ, a subsidiary of Sino Biopharmaceutical Limited) rovadicitinib (Anxu) -- a first-in-class oral JAK/ROCK dual inhibitor -- for $135M upfront plus up to $1.395B in development, regulatory and sales milestones and up to double-digit tiered royalties on net sales. Rovadicitinib won its first approval in China (NMPA, February 2026) for first-line intermediate-2/high-risk myelofibrosis (PMF, post-PV-MF, post-ET-MF). Chronic graft-versus-host disease (cGVHD) is the lead expansion indication: a Phase III cGVHD trial is ongoing in China and the asset has been cleared for Phase 2 development in the US for cGVHD. The agreement, signed March 4, 2026, remains subject to customary closing conditions, including regulatory clearances.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Chia Tai Tianqing Pharmaceutical Group (subsidiary of Sino Biopharmaceutical Limited) (this deal) | 2026 | $1.5B | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2026 deals · Sanofi SA deals · Hematology deals